Antiviral activity of HIV‐1 integrase strand‐transfer inhibitors against mutants with integrase resistance‐associated mutations and their frequency in treatment‐naïve individuals

Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment

(2018) Edwin DeJesus et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0

(2018) L Ryom et al.   HIV MEDICINE

Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks

(2018) Nicolas Margot et al.   JOURNAL OF CLINICAL VIROLOGY

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir

(2018) Maureen Oliveira et al.   Retrovirology

Canary in the Coal Mine? Transmitted Mutations Conferring Resistance to All Integrase Strand Transfer Inhibitors in a Treatment-Naive Patient

(2018) Kara S McGee et al.   Open Forum Infectious Diseases

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2017) Paul E Sax et al.   LANCET

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome

(2017) Michael E. Abram et al.   PLoS One

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

(2016) Manuel Tsiang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rare emergence of drug resistance in HIV-1 treatment -naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide

(2016) Nicolas A. Margot et al.   HIV CLINICAL TRIALS

HIV-1 Protease, Reverse Transcriptase, and Integrase Variation

(2016) Soo-Yon Rhee et al.   JOURNAL OF VIROLOGY

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

(2015) Paul E Sax et al.   LANCET

Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients

(2015) Rima Kulkarni et al.   HIV CLINICAL TRIALS

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients

(2014) Kirsten L White et al.   ANTIVIRAL THERAPY

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure

(2013) Anne-Geneviève Marcelin et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

(2013) Joseph J Eron et al.   LANCET INFECTIOUS DISEASES

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Emerging patterns and implications of HIV-1 integrase inhibitor resistance

(2012) Anna Maria Geretti et al.   CURRENT OPINION IN INFECTIOUS DISEASES

HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes

(2012) S. Reigadas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4

(2011) Nicolas A. Margot et al.   ANTIVIRAL RESEARCH

Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy

(2011) Benjamin Young et al.   ANTIVIRAL THERAPY

Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient

(2011) Sarita D Boyd et al.   ANTIVIRAL THERAPY

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

(2011) P. K. Quashie et al.   JOURNAL OF VIROLOGY

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

(2011) Jean-Michel Molina et al.   LANCET INFECTIOUS DISEASES

Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors

(2010) Francesca Ceccherini-Silberstein et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy

(2009) Damian J. McColl et al.   ANTIVIRAL RESEARCH